Group 1: Overview of the Doctoral Service Team's Visit - The 26th batch of the Doctoral Service Team conducted a three-day investigation focusing on the "Four Places" construction in Qinghai, high-altitude medicine, and red education, covering cities such as Xining, Haidong, and Haibei [1] - The visit included diverse topics from mushroom cultivation to yak farming, and from carbon fiber production to traditional Tibetan medicine, showcasing a rich and compact itinerary [1] Group 2: "Two Bombs, One Satellite" Spirit - The visit to the first nuclear weapon research base in China inspired the team, emphasizing the historical significance and the spirit of dedication to the nation [2] - The team members expressed a strong commitment to contribute to the country, resonating with the "Two Bombs, One Satellite" spirit, which emphasizes dedication and service [2] Group 3: High-Altitude Medical Development - The team learned about advancements in high-altitude medicine, including low-oxygen physiology and disease prevention, highlighting the long-term dedication of researchers like Academician Wu Tianyi [3] - The visit to Haidong's second people's hospital showcased advanced medical equipment and improved healthcare services, enhancing public health awareness [3] Group 4: Industrial Development in Qinghai - The investigation revealed a diverse industrial landscape in Qinghai, including clean energy, carbon fiber production, and the integration of traditional culture with modern industries [4][5] - The "photovoltaic + ecology + animal husbandry" model by Tianhe Solar was praised for its innovative approach to sustainable development [4] - The success of the edible fungus cultivation demonstration garden, which occupies 40% of Qinghai's market share, was highlighted as a model for industry-driven poverty alleviation [5] Group 5: Innovation in Digital Economy and Biotechnology - The establishment of a carbon-neutral data center by China Telecom was noted as a leading example of green development in the digital economy [6] - The extraction of natural astaxanthin from green algae at Haibei Yihai Biotechnology Co. was recognized as a significant advancement in high-value biotechnology [6] - The three-day visit served as a platform for the team to align their expertise with the developmental needs of Qinghai, fostering future collaborations [6]

周五，AgomAb Therapeutics(AGMB.US)登陆美股市场，开盘跌超13%，IPO价格为16美元。AgomAb Therapeutics是一家临床阶段生物制药公司，致力于开发针对免疫与炎症疾病的创新疾病修正疗法。公 司初期战略聚焦于存在高度未满足医疗需求的慢性纤维化适应症，通过抑制纤维化关键信号通路——转 化生长因子-β(TGFβ)通路发挥作用。其核心候选药物ontunisertib(AGMB-129)是一种选择性、强效的口 服胃肠道限制性ALK5(即TGFβR1)小分子抑制剂，主要针对纤维狭窄型克罗恩病(FSCD)。 ...

Core Viewpoint - AgomAb Therapeutics has made its debut on the US stock market with an IPO price of $16, experiencing an opening drop of over 13% [1] Company Overview - AgomAb Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative disease-modifying therapies for immune and inflammatory diseases [1] - The company's initial strategy targets chronic fibrotic indications with high unmet medical needs, specifically through the inhibition of the key signaling pathway involved in fibrosis, the Transforming Growth Factor-beta (TGFβ) pathway [1] Key Product Information - The core candidate drug, ontunisertib (AGMB-129), is a selective and potent oral small molecule inhibitor of ALK5 (TGFβR1), primarily aimed at treating Fibrostenotic Crohn's Disease (FSCD) [1]

格隆汇2月6日丨药明康德(603259.SH)在投资者互动平台表示，Chemistry 42属于另一家生物科技公司， 和药明康德无关。公司历来不自行开发新药，也没有用AI来开发新药。 ...

中国基金报记者 张舟 2月6日晚间，又有上市公司被证监会立案！ 据中国证监会官网消息，2026年1月7日，深圳市亚辉龙生物科技股份有限公司（以下简称亚辉龙）披露签署战略合作框架协议的公告，涉嫌误导性陈述。 近日，证监会已对亚辉龙立案调查。下一步，将在全面调查的基础上依法处理，切实维护市场健康发展。 亚辉龙当晚发布公告称，公司已于2026年2月6日收到中国证监会下发的《立案告知书》，因公司涉嫌信息披露违法违规，中国证监会决定对公司立案。 登录新浪财经APP 搜索【信披】查看更多考评等级 【导读】亚辉龙被中国证监会立案 亚辉龙对此表示，目前公司各项经营活动和业务均正常开展。立案调查期间，公司将积极配合中国证监会的相关工作，并严格按照相关法律法规和监管要 求及时履行信息披露义务。 截至2月6日收盘，亚辉龙日内跌0.55%，股价报14.45元/股，最新市值为83亿元，最新股东户数为1.28万户。 编辑：格林 校对：王玥 制作：舰长 审核：木鱼 ...

Group 1 - Morgan Stanley increased its stake in Innovent Biologics (01801) by 1,233,667 shares at a price of HKD 78.6975 per share, totaling approximately HKD 97.0865 million [1] - After the increase, the total number of shares held by Morgan Stanley is approximately 87,914,900, representing a holding percentage of 5.06% [1]

Group 1 - Morgan Stanley increased its stake in Innovent Biologics (01801) by 1,233,667 shares at a price of HKD 78.6975 per share, totaling approximately HKD 97.0865 million [1] - Following the increase, Morgan Stanley's total shareholding in Innovent Biologics reached approximately 87,914,900 shares, representing a stake of 5.06% [1]

签署后，各方积极就本次投资事项进行沟通、协商及推进，但由于市场环境剧烈变化，行业面临比较大 的下行压力，新增投资疫苗产业风险比较高，经各方审慎评估与友好协商，决定终止《经济发展合作协 议》《条款清单》及对外投资设立合资公司事项。自终止生效日起，任何一方不再承担任何义务和责 任。该终止事项已经公司于2026年2月6日召开的第八届董事会第八次会议审议通过，董事会同意终止本 次对外投资设立合资公司事项，并授权公司管理层与合作方确定并签署相关终止协议等事宜。 格隆汇2月6日丨康泰生物(300601.SZ)公布，公司于2025年3月21日召开第八届董事会第三次会议，审议 通过了《关于签订<经济发展合作协议><条款清单>暨对外投资设立合资公司的议案》。公司拟与阿斯 利康投资（中国）有限公司（简称"阿斯利康"）聚焦疫苗建立战略合作伙伴关系，并在北京经济技术开 发区（简称"经开区"）设立合资公司，该合资公司的注册资本预计为3.45亿元人民币（折合5000万美 元），公司与阿斯利康分别持有50%的股权，合资公司的投资总额预计为约4亿美元（约合27.6亿元人 民币），最终实际投资金额根据项目进展情况而定。 ...

格隆汇2月6日丨康泰生物(300601.SZ)公布，公司全资子公司北京民海生物科技有限公司（简称"民海生 物"）作为重要参与单位完成的"新发病毒性传染病快速确认与精准防控关键技术创新及应用"项目荣获 江苏省科学技术进步奖二等奖，系民海生物继荣获北京市科学技术进步奖二等奖、获批合成免疫学与疫 苗智造北京市重点实验室后，在科技创新领域取得的又一重要荣誉。该项目由江苏省疾病预防控制中心 牵头、省卫生健康委员会提名，民海生物凭借在肠道病毒灭活疫苗研发领域的核心技术创新与贡献，共 同荣获此项殊荣。 该项目直面新发病毒性传染病防控中"快速确认"与"精准防控"的关键难题，通过系列技术攻关，构建了 一套高效应对体系。其中，民海生物自主研发并提供关键技术支撑的肠道病毒灭活疫苗平台，是项目的 核心组成部分之一。该技术的创新性、实用性与科学价值，获得了评审专家的高度认可。公司基于该平 台研发的二价肠道病毒灭活疫苗（Vero细胞）及四价肠道病毒灭活疫苗（Vero细胞），已于2025年2月 分别成功获得国家药品监督管理局颁发的药物临床试验批准通知书，其中四价肠道病毒灭活疫苗（Vero 细胞）已处于Ⅰ期临床试验。目前全球尚无二价肠道病毒 ...

Core Viewpoint - The company announced the termination of the investment agreement with AstraZeneca due to significant market changes and high risks in the vaccine industry [1] Group 1: Investment Agreement - The company planned to establish a joint venture with AstraZeneca focusing on vaccines, with a registered capital of 345 million RMB (approximately 50 million USD) [1] - Both the company and AstraZeneca were to hold 50% equity in the joint venture, with a total investment estimated at around 400 million USD (approximately 2.76 billion RMB) [1] - The decision to terminate the investment was made after careful evaluation and discussions among the parties involved, acknowledging the high risks associated with new investments in the vaccine sector [1] Group 2: Board Decisions - The termination of the investment agreement was approved during the company's eighth board meeting held on February 6, 2026 [1] - The board authorized the management to finalize and sign the relevant termination agreements with the partners [1]